Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.Teva's generic equivalent of Forteo (teriparatide injection) utilizes the Antares Pharma, Inc.

Teva Pharmaceutical Industries Ltd.（Teva）的美国分公司Teva Pharmaceuticals Inc.周五宣布在美国批准仿制药Forteo。根据IQVIA数据，截至2023年7月，Forteo的年销售额为6.09亿美元。Teva的Forteo（特立帕肽注射液）的通用等效物使用Antares Pharma，Inc。

multi-dose pen device. Teriparatide injection is indicated to treat osteoporosis among certain women and men.The market availability of the drug-device combination product in the U.S. is expected in the coming weeks..

多剂量笔设备。特立帕肽注射液适用于治疗某些女性和男性的骨质疏松症。预计未来几周美国药品-器械组合产品的市场可用性。。

Antares, a wholly owned subsidiary of Halozyme Therapeutics, Inc., and Teva are parties to an exclusive license, development and supply agreement for Teriparatide auto injector product that Teva markets in the EU and will market in the U.S. For comments and feedback contact: editorial@rttnews.comBusiness News.

Halozyme Therapeutics，Inc。的合资子公司Antares和Teva是Teva在欧盟市场销售的特立帕肽自动注射器产品独家许可，开发和供应协议的缔约方，并将在美国上市以获取意见和反馈联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In November 2023

2023年11月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In October 2023

2023年10月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票